Peter Carmeliet

Peter Carmeliet (Dutch: [ˈpeːtər ˈkɑrməliːt]) is a Belgian physician and professor at the Katholieke Universiteit Leuven (Leuven, Belgium). He is also Adjunct Director of the VIB Department of Transgene Technology and Gene Therapy, KU Leuven. Among his research interests are vasculogenesis, angiogenesis, and vascular endothelial growth factor (VEGF).[1][2][3]

Awards

References

  1. Carmeliet P, Ferreira V, Breier G, Pollefeyt S, Kieckens L, Gertsenstein M, Fahrig M, Vandenhoeck A, Harpal K, Eberhardt C, Declercq C, Pawling J, Moons L, Collen D, Risau W, Nagy A, Abnormal blood vessel development and lethality in embryos lacking a single VEGF allele, Nature 380, 435-439, 1996
  2. Ferrara N, Carver-Moore K, Chen H, Dowd M, Lu L, O’Shea KS, Powell-Braxton L, J. Hillan K, W. Moore M, Heterozygous embryonic lethality induced by targeted inactivation of the VEGF gene, Nature 380, 439-442, 1996
  3. Fischer C, Jonckx B, Mazzone M, Zacchigna S, Loges S, Pattarini L, Chorianopoulos E, Liesenborghs L, Koch M, De Mol M, Autiero M, Wyns S, Plaisance S, Moons G, Van Rooijen N, Giacca M, Stassen J, Dewerchin M, Collen D, Carmeliet P, Anti-PlGF Inhibits Growth of VEGF(R)-Inhibitor-Resistant Tumors without Affecting Healthy Vessels, Cell 131, 463-75, 2007
  4. Bloom S., Belgian scientists awarded top honors, J Clin Invest. 2005 May;115(5):1106-7
  5. http://www.kuleuven.be/ci/28/ci28_carmeliet.html

External links


This article is issued from Wikipedia - version of the Sunday, March 13, 2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.